An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat.
about
Update on human herpesvirus 6 biology, clinical features, and therapyPathogenesis of human immunodeficiency virus infectionSynergistic activation of the human immunodeficiency virus type 1 promoter by the viral Tat protein and cellular transcription factor Sp1Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factorsHuman herpesvirus 6Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidineMutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphomaThe Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sitesHuman herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancerThe C-terminal region but not the Arg-X-Pro repeat of Epstein-Barr virus protein EB2 is required for its effect on RNA splicing and transportThe Epstein-Barr virus (EBV) SM protein enhances pre-mRNA processing of the EBV DNA polymerase transcript.The human herpesvirus 8 homolog of Epstein-Barr virus SM protein (KS-SM) is a posttranscriptional activator of gene expressionEpstein-Barr virus SM protein interacts with mRNA in vivo and mediates a gene-specific increase in cytoplasmic mRNA.Activation of the human immunodeficiency virus type 1 long terminal repeat by vaccinia virus.Functional analysis of Epstein-Barr virus SM protein: identification of amino acids essential for structure, transactivation, splicing inhibition, and virion productionNatural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1.The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R.Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.The Epstein-Barr virus nuclear protein SM is both a post-transcriptional inhibitor and activator of gene expression.The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversionThe effects of cytomegalovirus on human immunodeficiency virus replication in brain-derived cells correlate with permissiveness of the cells for each virusTAR-independent transactivation of the murine cytomegalovirus major immediate-early promoter by the Tat proteinThe Epstein-Barr virus (EBV) early promoter DR contains a cis-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities.The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters.The Epstein-Barr virus BZLF1 gene product activates the human immunodeficiency virus type 1 5' long terminal repeat.ZEBRA and a Fos-GCN4 chimeric protein differ in their DNA-binding specificities for sites in the Epstein-Barr virus BZLF1 promoter.Identification of a transactivating function mapping to the putative immediate-early locus of human herpesvirus 6Identification of the human herpesvirus 6 glycoprotein H and putative large tegument protein genes.An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivatorsFeline leukemia virus infection as a potentiating cofactor for the primary and secondary stages of experimentally induced feline immunodeficiency virus infection.Persistent nonproductive infection of Epstein-Barr virus-transformed human B lymphocytes by human immunodeficiency virus type 1.The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent.Cytomegalovirus activates transcription directed by the long terminal repeat of human immunodeficiency virus type 1.The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner.The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes.Human cytomegalovirus inhibits human immunodeficiency virus replication in cells productively infected by both virusesResponsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions.The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a posttranscriptional mechanism which is reporter gene dependent.The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivatorsEpstein-Barr virus-positive and -negative B-cell lines can be infected with human immunodeficiency virus types 1 and 2.
P2860
Q24557543-42F52EE9-D5C9-4748-8767-EB3640E5A4A8Q24634681-212B388C-CBE7-4C43-A9B4-4BE0543E42F2Q24644981-FE578075-D856-41E0-A6F3-F576C2D54660Q24651506-A007FEB8-C5E2-4C3F-97B9-24451BB0222FQ24683663-6512CB74-2903-4419-816C-EBF06D049ADDQ28340298-E0360C27-BA8A-4977-9C3A-269A87E7EE34Q28472086-925A7166-CA3D-4F8C-9BBB-83A906E1D113Q33565012-E0185854-CBBD-4ED2-808C-B609B272D6F6Q33581303-3F5B1956-539A-4100-9FE6-C42CE77241BCQ33647481-CEA93564-166D-4CDE-BC30-7696CAA51A6DQ33785161-B263E175-E185-49AE-9479-2E97E72D2604Q33796895-8A776976-2154-4B9E-8AC1-A9783D534B2EQ33842488-8CD961F4-FE2C-44EE-AFD6-68A4C545FD7FQ33930958-49B7BE6C-C5CB-4C9A-9A51-A3A36C8F3E36Q34552876-3FFBD43C-93BF-45AE-B1CA-B018CC16C200Q35178721-0DF14C0C-50CB-452A-8F69-CCC7913CAA8FQ35537283-BE809D00-9DF0-435E-94F4-588B908C8D03Q35870516-8A355928-6008-4EA0-AE5E-70888D42FD88Q36224577-C4CCC842-D876-4B1E-A6C3-55031ABE308AQ36503545-21F0BC85-9FA6-464F-8C9C-1C319884C190Q36626966-0AA81C68-5A9A-4F1A-A651-69D96394F7EEQ36639281-D53FC571-2328-418A-91F6-1CF33ECEFF59Q36780602-DCF93926-4E18-4DF2-9986-45942ABBE3C7Q36792029-E71271DD-7A75-4B53-8762-488EF8E27D49Q36796351-38A8E25C-6D8B-4E90-B307-91C75B383C73Q36797008-55841280-53A3-4A4E-8359-10FE758FBDE6Q36798152-73CDA436-67D7-4D73-B56A-27C0BB5B55B9Q36798697-BCBB652D-154D-4792-85AF-8B4486BFCDEBQ36799401-392F61F6-0948-4C50-A6D2-8EE1C13D897AQ36800507-896A5CEC-F70E-4CD1-BF1E-687934A4B864Q36804062-91A4AFA4-3C08-4FB5-A065-FFF91D0B5DB1Q36804236-0A4F38A7-FBA8-44C7-886D-36C4B0304CB4Q36807977-B9B3C321-03CF-46E4-ABEA-C19890702526Q36812174-400AF1AB-4368-4820-BE1C-B5F60E657248Q36827125-D3545280-6EC9-4993-B01A-3E4B07C86A8DQ36829008-BF64D24D-1016-478B-A03A-419A36A146D3Q36829336-4AFA650E-B706-427A-B8BF-62068CD28772Q36830488-D2DC154B-BA05-4596-833E-8AB6BB727FB6Q36830501-787F1C64-BDB8-4066-A935-A50C653912DAQ36872675-64548E9B-40CF-4FA5-97CC-5059B9F941F2
P2860
An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat.
description
1988 nî lūn-bûn
@nan
1988 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի մարտին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
An Epstein-Barr virus immediat ...... cy virus long terminal repeat.
@ast
An Epstein-Barr virus immediat ...... cy virus long terminal repeat.
@en
An Epstein-Barr virus immediat ...... cy virus long terminal repeat.
@nl
type
label
An Epstein-Barr virus immediat ...... cy virus long terminal repeat.
@ast
An Epstein-Barr virus immediat ...... cy virus long terminal repeat.
@en
An Epstein-Barr virus immediat ...... cy virus long terminal repeat.
@nl
prefLabel
An Epstein-Barr virus immediat ...... cy virus long terminal repeat.
@ast
An Epstein-Barr virus immediat ...... cy virus long terminal repeat.
@en
An Epstein-Barr virus immediat ...... cy virus long terminal repeat.
@nl
P2093
P2860
P356
P1476
An Epstein-Barr virus immediat ...... cy virus long terminal repeat.
@en
P2093
P2860
P304
P356
10.1073/PNAS.85.5.1652
P407
P577
1988-03-01T00:00:00Z